We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Biota Fpo | ASX:BTA | Australian Stock Exchange | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.00 | - |
From Jul 2019 to Jul 2024
Biota Holdings Ltd. (BTA.AU) said Friday the Australian government will spend A$43 million to almost double its Relenza stockpile.
Biota said that the government will buy an extra 1.6 million courses to bolster its supplies of antiviral drugs to treat pandemic influenza.
The drug is made by GlaxoSmithKline PLC (GSK) under license and Biota earns a 10% royalty on all Australian sales of Relenza, it said in a statement.
On completion of the contract, the stockpile will include 3.4 million courses of Relenza, which comprises one-third of the total stockpile of influenza antivirals, Biota said.
-By Andrew Harrison, Dow Jones Newswires; 61-3-9292-2095; andrew.harrison@dowjones.com
1 Year Biota Holdings Chart |
1 Month Biota Holdings Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
